Pnd70 Evaluating the Importance of Drug Administration and Monitoring Costs in Economic Evaluation for Management of Multiple Sclerosis in the United Kingdom

Abstract

IQVIA. Numbers of prescriptions and purchases (in $Can) were collected for 12month periods ending November for the past five years (2015)(2016)(2017)(2018)(2019). Results: The Canadian market for psychostimulants for ADHD has grown steadily since 2015, with prescriptions increasing by 53% (from 4.4 million in 2015 to 6.7 million in 2019) and total drugstore and hospital purchases increasing by 56% (from $330 million in 2015 to $515 million in 2019). Methylphenidates led the market in terms of prescriptions over the past five years (60%), while capturing 50% of purchases. Generic forms of psychostimulants accounted for 18.5% of prescriptions and 4.8% of purchases in the 12 months ending November 2019, up from 14.5% and 4.3%, respectively, in the 12 months ending November 2015. The contribution of lisdexamfetamine dimesylate has grown markedly over the past five years, with prescriptions increasing 90% and sales doubling from 2015 to 2019. In contrast, purchases of mixed salts amphetamine declined by 20% despite a 17% increase in prescriptions. Conclusions: Psychostimulants accounted for 90% of ADHD drug purchases in 2019, representing a market of $515 million dollars in Canada that has grown steadily since 2015.